The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2020 | Lung ART trial updates from ESMO 2020
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, summarizes the key findings of the Lung ART trial (NCT00410683) which investigated postoperative conformal radiotherapy (PORT) in patients with completely resected non-small-cell lung cancer (NSCLC) and mediastinal N2 involvement. Treatment using adjuvant PORT was associated with a non-statistically significant 15% increase in disease-free survival (DFS). Prof. Popat discusses a potential benefit for the therapy in other patient groups. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
